Media formats available:


Mederma Introduces Scar Gel

Mederma's new Advanced Scar Gel is available for the reduction of the overall appearance of scars caused by injury, acne, surgery, or burns with one daily application. The product contains Cepalin, the same proprietary botanical extract derived from onions used in all Mederma scar products and stretch marks therapy. In a recent study, individuals reported an average of 36 percent greater improvement in the overall appearance of scars treated with Mederma Advanced Scar Gel after eight weeks of once-daily use. For best results, Mederma Advanced Scar Gel should be applied evenly and gently rubbed into the scar once daily for eight weeks on new scars and three to six months on existing scars.

Skin Cell Restoration Product Released

Makucell introduced a new skin care line that offers a novel approach to cellular aging. The Renewnt brand proprietary molecule, Asymmtate, an original technology platform, is a selective synthetic modulator that encourages skin stem cells to differentiate. It penetrates the epidermis and dermis to help the skin's own stem cells replenish keratinocytes, fibroblasts, and other dermal cells. It is non-mutagenic, non-irritating, and non-sensitizing.

Revision Introduces New

A new product has joined the Revision Skincare line. The Teamine Concealer incorporates a variety of ingredients from around the world and helps to conceal under-eye imperfections in addition to improving the appearance of dark circles, fine lines, wrinkles, and puffiness in four to eight weeks.


Laser Secures Indication for Treatment of Onychomycosis

The Harmony(XL) multi-application, multi-technology platform (ALma Lasers) gained FDA clearance for a novel approach to the treatment of nail fungus. The new application allows for two distinct laser technologies to treat the appearance of nail fungus from the inside out. The Q-Switched 1064nm Nd:YAG laser, with its KTP 532-nm tip, creates micro-cavitations and acoustic shock waves on the surface of the nail plate. These then get transmitted to the nail bed, causing mechanical damage in the irradiated fungal colony, which may decapsulate the fungus spores.


Eli Lilly's Experimenta l Psoriasis Agent Meets Goals

Eli Lilly announced that its experimental psoriasis drug ixekizumab was more effective than a placebo at treating moderate to severe plaque psoriasis in a mid-stage clinical trial. The study compared the number of patients who experienced at least a 75-percent reduction in their psoriasis symptoms after 12 weeks of treatment with ixekizumab to patients who had that level of improvement after being injected with the placebo. Patients received one injection every two weeks for the first two months of the study and one injection every four weeks after that. Results indicated that patients who were treated with doses of 25 milligrams, 75 milligrams, and 150 milligrams had significantly greater improvement. In those groups, the company said 77 percent, 83 percent, and 82 percent of patients, respectively, met the main target in the study. That compares to 8 percent of patients in the placebo group.

Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free